Format

Send to

Choose Destination
Lancet Oncol. 2015 Nov;16(15):e555-e567. doi: 10.1016/S1470-2045(15)00005-4.

Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.

Author information

1
Haematology Department, Hospices Civils de Lyon, Lyon, France; University Lyon 1, Lyon, France.
2
Service d'Anatomie Pathologique, Hospices Civils de Lyon, Lyon, France; University Lyon 1, Lyon, France.
3
Haematology Department, Hospices Civils de Lyon, Lyon, France; University Lyon 1, Lyon, France. Electronic address: Bertrand.coiffier@chu-lyon.fr.

Abstract

Double-hit lymphoma (DHL) is a subgroup of aggressive lymphomas with both MYC and BCL2 gene rearrangements, characterised by a rapidly progressing clinical course that is refractory to aggressive treatment and short survival. Over time, the definition was modified and now includes diffuse large B-cell lymphoma (DLBCL) with MYC translocation combined with an additional translocation involving BCL2 or BCL6. Some cases that have a similar clinical course with concomitant overexpression of MYC or BCL2 proteins were recently characterised as immunohistochemical double-hit lymphomas (ie, double-protein-expression lymphomas [DPLs]). The clinical course of these DPLs is worse than so-called standard DLBCL but suggested by some studies to be slightly better than DHL, although there is overlap between the two categories. Present treatment does not allow cure or long-term survival in patients with genetic or immunohistochemical double-hit lymphomas, but several new drugs are being developed.

PMID:
26545844
DOI:
10.1016/S1470-2045(15)00005-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center